Skip to main content

Advertisement

SpringerLink
Log in

Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab

  • Rapid Communication
  • Published:
Modern Rheumatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580–4.

    Article  CAS  PubMed  Google Scholar 

  2. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–23.

    Article  CAS  PubMed  Google Scholar 

  3. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.

    Article  CAS  PubMed  Google Scholar 

  4. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.

    Article  CAS  PubMed  Google Scholar 

  5. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–80.

    Article  CAS  PubMed  Google Scholar 

  6. den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34(4):689–95.

    Google Scholar 

  7. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol. 2010;29(5):495–500.

    Article  PubMed  Google Scholar 

  8. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55(2):333–7.

    Article  PubMed  Google Scholar 

  9. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25(3):430–6.

    CAS  PubMed  Google Scholar 

  10. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford). 2010;49(2):341–7.

    Article  CAS  Google Scholar 

  11. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20(4):250–78 (quiz 279–80).

  12. Hirao M, Hashimoto J, Tsuboi H, Nampei A, Nakahara H, Yoshio N, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2009;68(5):654–7.

    Article  CAS  PubMed  Google Scholar 

  13. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 2005;44(2):157–63.

    Article  CAS  Google Scholar 

  14. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Ethics approval

Ethics approval was obtained. These patients participated in a large-scale Japanese RA cohort project, IORRA. The details of the study were explained to each patient by rheumatologists during clinic visits, and informed consent was received from each patient.

Conflict of interest

Dr. Kosei Kawakami, Dr. Takuji Iwamoto, and Dr. Asami Tokita received speaking fees from Mitsubishi Tanabe Pharma Corporation. Dr. Katsunori Ikari received speaking fees and/or honoraria from Abbott Japan Co., Ltd. and Mitsubishi Tanabe Pharma Corporation. Dr. Shigeki Momohara received speaking fees and/or honoraria from Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Wyeth K.K. The other authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada, Shinjuku, Tokyo, 162-0054, Japan

    Ryo Hiroshima, Kosei Kawakami, Takuji Iwamoto, Asami Tokita, Koichiro Yano, Yu Sakuma, Katsunori Ikari & Shigeki Momohara

Authors
  1. Ryo Hiroshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kosei Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuji Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Asami Tokita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koichiro Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Sakuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katsunori Ikari
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shigeki Momohara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeki Momohara.

About this article

Cite this article

Hiroshima, R., Kawakami, K., Iwamoto, T. et al. Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab. Mod Rheumatol 21, 109–111 (2011). https://doi.org/10.1007/s10165-010-0343-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-010-0343-1

Keywords

Search

Navigation